Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Change in Acquisitions & Divestments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 66.25% to $27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.9 million, a 19.57% decrease, with the full-year FY2025 number at $252.9 million, down 19.57% from a year prior.
  • Change in Acquisitions & Divestments was $27.0 million for Q4 2025 at Lexicon Pharmaceuticals, down from $78.8 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $105.6 million in Q1 2025 to a low of $27.0 million in Q4 2025.
  • A 3-year average of $61.8 million and a median of $58.5 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 192.12% in 2024, then plummeted 66.25% in 2025.
  • Lexicon Pharmaceuticals' Change in Acquisitions & Divestments stood at $52.0 million in 2023, then soared by 53.85% to $80.0 million in 2024, then tumbled by 66.25% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Change in Acquisitions & Divestments are $27.0 million (Q4 2025), $78.8 million (Q3 2025), and $41.5 million (Q2 2025).